One-year experience of hybrid closed-loop system in children and adolescents with type 1 diabetes previously treated with multiple daily injections: drivers to successful outcomes

Goran Petrovski1 · Fawziya Al Khalaf1 · Judith Campbell1 · Fareeda Umer1 · Douha Almajaly1 · Manar Hamdan1 · Khalid Hussain1

Received: 16 August 2020 / Accepted: 17 September 2020 / Published online: 12 October 2020
© The Author(s) 2020

Abstract
Objective To evaluate the effect of a 1-year hybrid closed-loop (HCL) system on glycemic control in children and adolescents with type 1 diabetes (T1D) previously treated with multiple daily injections (MDI).

Methods This was a 1-year observational study, as a continuation of the previous 3 months prospective study of pediatric patients with T1D conducted at Sidra Medicine in Qatar. The study enrolled individuals aged 7–18 years with T1D > 1 year, on MDI with self-monitoring of blood glucose or continuous glucose monitoring, with no prior pump experience, and with an HbA1c level < 12.5% (< 113 mmol/mol). After the first 3 months of HCL use, patients were followed at 6, 9 and 12 months, where HbA1c was obtained and pump data were collected.

Results All 30 participants (age 10.24 ± 2.6 years) who initiated HCL completed 12 months of HCL system use in Auto Mode. The participants used the sensor 88.4 ± 6.5% of the time with Auto Mode usage 85.6 ± 7.4% during 12 months of HCL system use. HbA1c decreased from 8.2 ± 1.4% (66 ± 15.3 mmol/mol) at baseline, to 6.7 ± 0.5% (50 ± 5.5 mmol/mol) at 3 months (p = 0.02) and remained stable to 7.1 ± 0.6 (54 ± 6.6 mmol/mol) at 12 months (p = 0.02). TIR (70–180 mg/dL) increased from 46.9% at baseline to 71.9% at 1 month and remained above 70% during the 12 months of HCL use.

Conclusion HCL system (MiniMed 670G) in children and adolescents previously treated with MDI significantly improves glycemic outcomes (HbA1c and Time in Ranges) immediately during the first month. This improved glycemic control was maintained over the 1 year following Auto Mode initiation.

Keywords Type 1 diabetes · Continuous subcutaneous insulin infusion · Continuous glucose monitoring · Diabetes education · Closed-loop systems

Introduction
The use of diabetes technology is a promising treatment strategy to improve diabetes outcomes. The use of Continuous Subcutaneous Insulin Infusion (CSII) and Continuous Glucose Monitoring (CGM) is associated with a reduction in HbA1c, both when used separately and together [1]. Recent technological advances have integrated CSII with CGM, where insulin delivery can be automated by sensor glucose (SG) driven algorithms. Insulin delivery suspension when reaching a low glucose level [2, 3] or in the prediction of a low glucose level [4, 5] has demonstrated a significant reduction in hypoglycemia exposure. Closed-loop systems are designed to maintain glucose levels at a predetermined target by linking CGM information with an insulin dosing algorithm for automated subcutaneous insulin delivery by a pump [6].

The MiniMed 670G [7] is the first hybrid closed-loop (HCL) insulin delivery system for use in diabetes care since 2017 and uses an algorithm to adjust basal insulin delivery automatically every 5 min based on SG values [8]. Several short-term studies on the HLC system have shown improved HbA1c, time in target range, and
SG variability in children [9], adolescents and adults [10, 11]. Glycemic outcomes in the pediatric age have been traditionally lower, while the causes are not clear and the underlying causes are to be defined. Three-month observational study [12] has shown that children and adolescents with T1D on MDI therapy without prior pump experience can successfully initiate the HCL system, using a concise structured 10-day protocol and achieve better glycemic outcome than previous treatment with MDI. Another study on the HCL system in children and youth with T1D shows that glycemic control is improved with Auto Mode use when measured by percent TIR, SG and HbA1c during the 6 months follow-up [13].

It remains to be determined whether these short-term effects on improved glycemic control with HCL systems are maintained in the long-term period. Long-term effect (6 and 12 months) of HCL shows scarce results in terms of Auto Mode usage, sensor wear, HbA1c, time in the target range and pump discontinuation [13–16]. The objective of this study was to evaluate the effect of a 1-year HCL system on glycemic control in children and adolescents with T1D previously treated with MDI.

**Methods**

This was a 1-year observational study, as a continuation of the previous 3-month prospective study [12] of pediatric patients with T1D conducted at Sidra Medicine in Doha, Qatar. The study enrolled individuals aged 7–18 years with T1D > 1 year, on MDI with SMBG, with or without real-time or intermittent CGM, with no prior pump experience, and with an HbA1c level < 12.5%.

The patient selection, the educational process, as well as the 10-day initiation protocol for the MiniMed 670G HCL system were previously reported [12]. In short, the 10-day initiation protocol consisted of four main stages: Step 1- HCL system compatibility assessment: two 1 h introduction sessions in groups of 8–12 patients, where the MiniMed 670G system was described and individuals’ responsibilities and expectations were discussed; Step 2- HCL system training: five sessions of 2 h on five consecutive days in groups of 3–5 patients, where CGM was initiated the first day of the training for education and observational purposes and the pump was used as a monitor (insulin delivery with injections); Step 3- Manual Mode: HCL system initiation in Manual Mode for 72 h; Step 4- Auto Mode: HCL system initiation and used continuously for 3 months.

After the first 3 months of HCL use, patients would then be seen for routine follow-up at 6, 9 and 12 months.

Demographics and other data (age, gender, and weight, and height, number of visits, diabetes duration and prior CGM use) were collected from the electronic medical record (Power Chart, Cerner Corporation, Kansas City, USA).

Insulin dosing information and CGM data were collected from CareLink Therapy Management Software (Medtronic, Northridge, USA) during the study.

HbA1c was obtained using point of care DCA Vantage Analyzer (Siemens, Erlangen, Germany) at baseline, 3, 6, 9 and 12 months during the study.

The study was approved by the local and National Ethics Committee in Qatar, and all participants and their guardians signed informed consent documents.

**Statistical analysis**

Analysis was performed for the entire study population. The data are presented as mean ± SD, median, interquartile or as a percentage. The paired student t-test or paired Wilcoxon test, in case of non-normality, was used in the study. A value of 0.05 was considered statistically significant. Statistical analyses were performed using Statistica 12 (Stat Soft, Tulsa, USA).

**Results**

**Participants**

The 10-day initiation protocol was implemented in 30 participants (age 10.2 ± 2.6 years), and they all completed

| Participants N=30 |
|-------------------|
| Age, years | 10.2 ± 2.6 |
| Male, n (%) | 15 (50%) |
| Female, n (%) | 15 (50%) |
| Weight, kg | 38.2 ± 12.5 |
| BMI, kg/m² | 18.6 ± 3.4 |
| BMI, z-score | 0.2 ± 0.9 |
| Duration of diabetes, years | 2.8 ± 1.7 |
| TDD, U/(kg/d) | 0.8 ± 0.3 |
| HbA1c, % | 8.2 ± 1.4 |
| HbA1c, mmol/mol | 66 ± 15.3 |
| Number of visits per patients (3–12 months), n | 4.8 ± 0.4 |
| Sensor use, n (%) |
| RT CGM | 6 (20%) |
| isCGM | 10 (33%) |
| No sensor | 14 (47%) |

All values are shown as mean ± SD, except for gender and sensor use.
12 months of HCL system use in Auto Mode. Baseline characteristics are shown in Table 1.

**Glycemic control**

HbA1c decreased from $8.2 \pm 1.4\%$ ($66 \pm 15.3$ mmol/mol) at baseline, to $7.1 \pm 0.6$ ($54 \pm 6.6$ mmol/mol) at 12 months ($p = 0.02$), (Table 2).

The aggregated HbA1c over the 12-month period (calculated as the average of HbA1c at 3, 6, 9 and 12 months) was $6.9 \pm 0.7$ ($52 \pm 7.7$ mmol/mol), significantly lower than $8.2 \pm 1.4\%$ ($50 \pm 5.5$ mmol/mol) at baseline ($p = 0.02$).

Mean SG (24 h period) decreased from $193 \pm 41$ mg/dL at baseline to $149 \pm 18$ mg/dL during the 12-month period and was similar during each 3-month period (Table 2).

**Time in ranges evolution over time**

Time in range (71–180 mg/dL) increased from 46.9% at baseline to 73.4% ($p = 0.01$), over the 12-month period, while time above range (≥ 181 mg/dL) decreased from 49.9% to 23.9% ($p = 0.01$) and time below range did not change significantly.

Comparing different study periods, TIR (70–180 mg/dL) increased from MDI + CGM to Manual Mode ($p = 0.01$); Manual Mode to Auto Mode of 28 days ($p = 0.01$); Auto Mode of 28 days to 3 months ($p = 0.72$); Auto Mode of 3 months to 6 months ($p = 0.67$); Auto Mode of 6 months to 9 months ($p = 0.81$) and Auto Mode of 9 months to 12 months ($p = 0.77$), as shown in Fig. 1.

Time above range (≥ 181 mg/dL), decreased from 50% on MDI + CGM to 25.4% at Auto Mode of 28 days ($p = 0.02$), and was maintained below 25% during the study.

**Therapy-related changes**

TDD (Total Daily Dose) delivered, increased by 0.1 U/kg ($p = 0.02$) during the study, compared to baseline (Table 2) and the percent of basal insulin out of the TDD increased significantly from 36.5 ± 7.2 to 43.8 ± 9.8% during this interval.

Insulin to Carbohydrate Ratio (ICR) during the initial Auto Mode period was made more aggressive regardless of the meal period compared with baseline and decreased from $16.2 \pm 5.7$ g at the beginning to $12.8 \pm 5.2$ g at the third month of Auto Mode ($p = 0.01$), to $10.1 \pm 6.2$ g at the end of the study ($p = 0.01$). ICR in participants with HbA1c > 8.5% (69 mmol/mol) at baseline was significantly higher, $17.8 \pm 6.4$ g compared to $14.6 \pm 5.2$ g in participants with HbA1c < 7.0% (53 mmol/mol) at baseline ($p = 0.04$), without significant difference $13.2 \pm 5.6$ g to $12.5 \pm 4.2$ g at third month ($p = 0.58$), and $9.8 \pm 6.4$ g to $10.3 \pm 6.1$ g at the end of the study ($p = 0.76$), respectively.

**HCL system usability**

The participants used the sensor of 89.8 ± 7.5% of the time in the first 2 weeks after activating Auto Mode and did not change over the 12-month period, while Auto Mode usage remained constant above 85%.

The total number of Auto Mode exits significantly decreased between the first 2 weeks and the first 3 months after enabling Auto Mode, from $8.4 \pm 1.8$ to $4.2 \pm 0.9$ events per week, respectively ($p = 0.01$), and remained stable during other study periods (Table 3).

Tarble 2 Glucose control, HbA1c, insulin delivered during baseline and study phase

|                  | MDI, Baseline | HCL, 1–3 months | $p$  | HCL, 4–6 months | $p$  | HCL, 7–9 months | $p$  | HCL, 10–12 months | $p$  |
|------------------|---------------|-----------------|------|-----------------|------|-----------------|------|-------------------|------|
| HbA1c, %         | 8.2 ± 1.4     | 6.7± 0.8        | 0.02 | 6.9± 0.7        | 0.03 | 6.8 ± 0.5$^a$  | 0.03 | 7.1 ± 0.6$^a$     | 0.02 |
| HbA1c, mmol/mol  | 66 ±15.3      | 50± 8.7         |      | 52± 7.7         |      | 51 ± 5.5        |      | 54 ± 6.6          |      |
| SG (12 am–12 am), mg/dl | 193± 41     | 142± 12         | 0.01 | 146± 20         | 0.01 | 141 ± 14        | 0.01 | 149 ± 18          | 0.01 |
| SG (10 pm–06 am), mg/dl | 183± 35     | 133± 17         | 0.02 | 138± 16         | 0.02 | 132 ± 15        | 0.01 | 136 ± 14          | 0.02 |
| SG (06 am–10 pm), mg/dl | 202± 42     | 150± 10         | 0.01 | 145± 17         | 0.01 | 149 ± 12        | 0.02 | 155 ± 21          | 0.02 |
| Weight, kg       | 38.2± 12.5    | 39.4± 8.9       | 0.63 | 40.2± 8.1       | 0.61 | 41.7 ± 7.2      | 0.58 | 42.8 ± 8.2        | 0.50 |
| TDD, U/(kg/d)    | 0.8± 0.3      | 0.9± 0.2        | 0.02 | 0.9± 0.3        | 0.02 | 0.9 ± 0.3       | 0.02 | 0.9 ± 0.5         | 0.02 |
| Basal insulin, (12 am–12 am), % | 36.5± 7.2 | 42.2± 6.7       | 0.03 | 43.3± 8.8       | 0.04 | 42.5 ± 10.2     | 0.04 | 43.8 ± 9.8        | 0.04 |

Results presented as mean ± SD; $p$-value at 3 months represents change from baseline to 3 months; $p$-value at 6 months represents change from baseline to 6 months; $p$-value at 9 months represents change from baseline to 9 months; $p$-value at 12 months represents change from baseline to 12 months

$SG$ sensor glucose; $TDD$ total daily dose; $U$ units; $d$, day

$^a$Due to Covid-19 Pandemic and disruption in clinical services, HbA1c was obtained in 26/30 participants at 9 months and 27/30 participants at 12 months.
The number of daily calibrations also significantly decreased from 4.3 ± 1.2 in the first 2 weeks to 3.4 ± 0.9 at the first 3 months of Auto Mode use (p = 0.01) and remained similar throughout the 12 months. The number of meals and carbohydrate intake did not differ from the beginning to the end of the study.

Safety

There was no event of severe hypoglycemia, diabetic ketoacidosis (DKA) or hospital admission during the study. There were six episodes of hyperglycemic events (infusion blockage 4 and influenza 2) that needed medical attention by phone consultation with the diabetes team.

Discussion

This is the first 1-year study evaluating the effect of the HCL system on glycemic control in children and adolescents with T1D transitioning from MDI to advanced insulin delivery systems. The excellent outcomes and high retention of the participants for what is conceived as a
complex therapy can serve as a model for practices treating adolescents with T1D.

As the sensor wear time drives, the Auto Mode usage is required for better outcomes, and the 88.4 ± 6.5% sensor usage achieved at 12 months was one of the important achievements. This high percentage use of automation and no dropout rates can be attributed to the specific selection/initiation protocol including the initial use of the system as a sensor alone for 7 days, although the relative contribution of each component cannot be determined from the study. The study confirmed previous conclusions, that increased Auto Mode usage is associated with lower HbA1c and increased TIR, resulting in that patients with both higher sensor wear times and increased Auto Mode usage had incrementally lower HbA1c than patients with lower sensor wear time and less Auto Mode usage [17]. Our data showed high Auto Mode usage of 85.6% at 1 year, which is higher than 51% at 6 months after HCL initiation [13].

All 30 individuals enrolled in the 3-month prospective study [12] completed 1-year usage of the MiniMed 670G system with Auto Mode, and no attrition was observed, compared to 46% of participants, who stopped using the Auto Mode in the 1-year period reported by Lal et al. [16] and 19% discontinuation rate after 8 months, reported by Godwin et al. [18]. This can be partly due to the low number of Auto Mode exits, averaged 4.7 ± 2.0 per patient per week during the 12-month period, similar to 4.8 ± 1.6 exits at 3 months [9], which indicates that the participants were educated appropriately, and the system settings were optimized to reduce exits thus the system use became more comfortable over time. Participants’ high engagement and no attrition attest the effectiveness of the structured initiation HCL protocol, where realistic expectations and patient responsibilities were discussed and evaluated, as well as reflecting indirectly on the patient’s and caregiver’s satisfaction with the clinical and patients related outcomes.

This observational study confirms the potential of HCL systems to improve overall glycemic control [19, 20]. The 12 months observational results provide evidence for the sustainability of these results beyond the initial 3-month period reported previously [12] and are superior to previously reported outcomes in children [9] and adolescents [11]. The improved HbA1c in our study after 3 months remained stable in the long term with 7.1 ± 0.6% (54 ± 6.6 mmol/mol) at 1 year, compared to 7.6 ± 0.8 (60 ± 8.7 mmol/mol) at 1 year [16] and 7.2 ± 0.1 (55 ± 1.1 mmol/mol) at 6 months of HCL initiation [14] in previous reports. The HbA1c target of <7.0% (53 mmol/mol) established by the ADA and ISPAD guidelines for glycemic control in children [21, 22] was reached in 73% of the participants at the end of the study.

The International Consensus on CGM recommends that CGM metrics such as TIRs should be complementary to HbA1c in patient care [23]. The time spent within, below and above the target glycemic range have been defined as glycemic goals, beyond HbA1c [24, 25]. In our study, TIR (70–180 mg/dL) significantly increased to 74.8% at 3 months of Auto Mode use, which is higher than 68.8% in adolescents [11] and 64.6% in children [9] for the same study period. TIR (70–180 mg/dL) remained above 70% during the 1-year period, which is similar to 70.1% in adults [14], but significantly higher than 56.9% in youth [13], both at 6 months of HCL initiation. Time in range, time below range and time above range observed in our study, all achieved the desired clinical targets for CGM data interpretation [26].

The superior clinical outcomes in our study were most probably driven by the high sensor and Auto Mode use, and can be attributed to our specific selection/initiation protocol, the parental/guardian involvement and supervision of the children, as well as the support and follow-up by the diabetes team. The 10-day initiation HCL protocol for individuals on MDI enables the activation of the Auto Mode feature after 3 days of Manual Mode use, which is significantly shorter compared to 2–4 weeks, reported in other studies [9, 11, 27]. This shortened process might be better accepted by those initiating the technology. Proper settings of the pump in order to decrease patient being burdened by exits and additional SMBG requirements are important elements in the initiation and follow-up process. Modifying the ICR by increasing the meal bolus dose by almost 20% during the first month of Auto Mode use is necessary when initiating individuals on the HCL system from MDI regimens, which is similar to previous reports [28]. Our study shows that further strengthening of ICR was needed on the long-term period, as the TDD of insulin increases in children due to their growth and evaluation on ICR should be performed on each visit.

The observational period provided additional insight into the drivers for the improved clinical outcomes bestowed by the automated system. Both TDD and the percentage of daily basal insulin delivered, slightly increased, and the percentage of nightly basal insulin delivered slightly decreased, which effectively distributed the insulin delivery according to patients’ individual requirements, resulting in better control with minimal increase in total insulin dosages.

The improved clinical outcomes observed in our study were achieved in a safe manner, with no events of DKA, or severe hypoglycemia, and with no hospital admission. Several hyperglycemic events, which were noted during the study can be considered as regular issues in diabetes management in the real world. These events were managed by phone consultations without any impact on glycemic control or quality of life in the participants.

We acknowledge several limitations of our study: single center, absence of a control group and relatively small
number of participants. We did not analyze the quality of life, patient-reported outcomes and psycho-social and economic factors of the HCL system use. However, the objective of this study was to evaluate the long-term (1 year) effect of the HCL system on glycemic control.

Conclusion

In conclusion, whereas HCL systems, like the MiniMed 670G system, have demonstrated the potential to improve glycemic outcomes in the short-term period, our findings confirm that these improvements are maintained over a 1-year period following Auto Mode initiation. All individuals enrolled in this study completed 1-year usage of the MiniMed 670G system with Auto Mode with no dropouts, unlike the previously reported studies and a significant decrease of the calibration was observed. In our clinical practice, patients’ high engagement with the HCL system as well as structured follow-up, and appropriate pump settings were key contributors to achieve and maintain better glycemic control. Further investigation on a more varied larger population and patient satisfaction should be performed to confirm these findings.

Acknowledgments The authors thank the participants and their families for their collaboration during the study and acknowledge the contributions and the efforts of administration and research staff at Sidra Medicine for data management and analyses. The authors thank the consultants M.M, A.K., M.Z., A.E. and A.S. for their contribution in patient selection. G.P. researched the data and wrote the manuscript. F.A., J.C. and K.H. contributed to the discussion, reviewed and edited the manuscript. F.U. D.A. and M.H. contributed in the patients’ education and follow-up. G.P. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Funding Open Access funding provided by the Qatar National Library. This study (ClinicalTrials.gov NCT03755479) was funded by Sidra Medicine, Doha.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Ethical approval The study was approved by the local and National Ethics Committee in Qatar, and all participants and their guardians signed informed consent documents.

Human and animal rights All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2005.

Informed consent Informed consent was obtained from all patients for being included in the study.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Foster NC, Beck RW, Miller KM et al (2019) State of type 1 diabetes management and outcomes from the T1D exchange in 2016–2018. Diabetes Technol Ther 21:66–72
2. Ly TT, Nicholas JA, Retterath A et al (2013) Effect of sensor-augmented insulin pump therapy and automated insulin suspension vs standard insulin pump therapy on hypoglycaemia in patients with type 1 diabetes: a randomized clinical trial. JAMA 310(12):1240–1247
3. Bergenstal RM, Klonoff DC, Garg SK et al (2013) Threshold-based insulin pump interruption for reduction of hypoglycemia. N Engl J Med 369:224–232
4. Bosi E, Choudhary P, de Valk HW et al (2019) Efficacy and safety of suspend-before-low insulin pump technology in hypoglycaemia-prone adults with type 1 diabetes (SMILE): an open-label randomised controlled trial. Lancet Diabetes Endocrinol 7(6):462–472
5. Battelino T, Nimri R, Dovc K, Phillip M, Bratina N (2017) Prevention of hypoglycaemia with predictive low glucose insulin suspension in children with type 1 diabetes: a randomized controlled trial. Diabetes Care 40:764–770
6. Leelarathna L, Dellweg S, Mader JK et al (2014) Day and night home closed-loop insulin delivery in adults with type 1 diabetes: three-center randomized crossover study. Diabetes Care 37:1931–1937
7. U.S. Food and Drug Administration (2019) FDA approves first automated insulin delivery device for type 1 diabetes. Available from www.fda.gov/news-events/press-announcements/fda-approves-first-automated-insulin-delivery-device-type-1-diabetes. Accessed 21Mar2019
8. Weaver KW, Hirsch IB (2018) The hybrid closed-loop system: evolution and practical applications. Diabetes Technol Ther 20(S2):S216–S223
9. Forlenza GP, Pinhas-Hamiel O, Liljenquist DR et al (2019) Safety evaluation of the MiniMed 670G system in children 7–13 years of age with type 1 diabetes. Diabetes Technol Ther 21(1):11–19
10. Bergenstal RM, Garg S, Weinzimer SA et al (2016) Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes. JAMA 316:1407–1408
11. Garg SK, Weinzimer SA, Tamborlane WV et al (2017) Glucose outcomes with the in-home use of a hybrid closed-loop insulin delivery system in adolescents and adults with type 1 diabetes. Diabetes Technol Ther 19:155–163
12. Petroski G, Al Khalaif F, Campbell J et al (2020) 10-Day structured initiation protocol from multiple daily injection to hybrid closed-loop system in children and adolescents with type 1 diabetes. Acta Diabetol 57:681–687
13. Berget C, Messer LH, Vigers T et al (2020) Six months of hybrid closed loop in the real-world: an evaluation of children and young adults using the 670G system. Pediat Diabetes 21(2):310–318
14. Akturk HK, Giordano D, Champakanath A, Brackett S, Garg S, Snell-Bergeon J (2020) Long-term real-life glycemic outcomes with hybrid closed-loop system when compared with sensor-augmented pump therapy in patients with type 1 diabetes. Diabetes Obes Metab 22(4):S83–S89
15. Messer LH, Berget C, Vigers T et al (2020) Real world hybrid closed-loop discontinuation: predictors and perceptions of youth discontinuing the 670G system in the first 6 months. Pediat Diabetes 21(2):319–327
16. Lal RA, Basina M, Maahs DM, Hood K, Buckingham B, Wilson DM (2019) One year clinical experience of the first commercial hybrid closed-loop. Diabetes Care 42(12):2190–2196
17. Duffus SH, Ta’ani ZA, Slaughter JC, Niswender KD, Gregory JM (2020) Increased proportion of time in hybrid closed-loop “Auto Mode” is associated with improved glycemic control for adolescent and young patients with adult type 1 diabetes using the MiniMed 670G insulin pump. Diabetes Obes Metab 22(4):688–693
18. Goodwin D, Waldman G, Lyons J, Oladunjoye A, Steil G (2019) Challenges in implementing hybrid closed loop insulin pump therapy (Medtronic 670G) in a ‘real world’ clinical setting. J Endocrinol Soc 3(Suppl. 1):OR14–15
19. Dai X, Luo ZC, Zhai L, Zhao WP, Huang F (2018) Artificial pancreas as an effective and safe alternative in patients with type 1 diabetes mellitus: a systematic review and meta-analysis. Diabetes Ther 9(3):1269–1277
20. American Diabetes Association (2019) Glycemic targets: standards of medical care in diabetes-2019. Diabetes Care 42(11):S61–S70
21. DiMeglio LA, Acerini CL, Codner E et al (2018) ISPAD clinical practice consensus guidelines 2018: glycemic control targets and glucose monitoring for children, adolescents, and young adults with diabetes. Pediat Diabetes 19(S27):105–114
22. Weisman A, Bai JW, Cardinez M, Kramer CK, Perkins BA (2017) Effect of artificial pancreas systems on glycaemic control in patients with type 1 diabetes: a systematic review and meta-analysis of outpatient randomised controlled trials. Lancet Diabetes Endocrinol 5:501–512
23. Danne T, Nimri R, Battelino T et al (2017) International consensus on use of continuous glucose monitoring. Diabetes Care 40:1631–1640
24. Rodbard D (2017) Continuous glucose monitoring: a review of recent studies demonstrating improved glycemic outcomes. Diabetes Technol Ther 19(5):S25–S37
25. Wright LA, Hirsch IB (2017) Metrics beyond hemoglobin A1C in diabetes management: time in range, hypoglycemia, and other parameters. Diabetes Technol Ther 19(5):S16–26
26. Battelino T, Danne T, Bergenstal RM et al (2019) Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care 42:1593–1603
27. Aleppo G, Webb KM (2018) Integrated insulin pump and continuous glucose monitoring technology in diabetes care today: a perspective of real-life experience with the MiniMed™ 670G hybrid closed-loop system. Endocr Pract 24(7):684–692
28. Messer LH, Forlenza GP, Sherr JL et al (2018) Optimizing hybrid closed-loop therapy in adolescents and emerging adults using the MiniMed 670G system. Diabetes Care 41(4):789–796

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.